Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesis
Latest Information Update: 21 Jan 2026
At a glance
- Drugs Naronapride (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Therapeutic Use
- Acronyms MOVE-IT
- Sponsors Dr Falk Pharma
Most Recent Events
- 08 Jan 2026 According to Renexxion media release, full study read out expected in Q1 2026.
- 08 Jan 2026 Status changed from active, no longer recruiting to completed, according to Renexxion media release.
- 27 May 2025 Status changed from recruiting to active, no longer recruiting, According to Renexxion media release.